Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features.

about

Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features.

Item

http://www.wikidata.org/entity/Q49909339

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Somatic BRCA1 mutations in cli ...... dullary histological features.

@en

Somatic BRCA1 mutations in cli ...... dullary histological features.

@nl

type

Item

label

Somatic BRCA1 mutations in cli ...... dullary histological features.

@en

Somatic BRCA1 mutations in cli ...... dullary histological features.

@nl

prefLabel

Somatic BRCA1 mutations in cli ...... dullary histological features.

@en

Somatic BRCA1 mutations in cli ...... dullary histological features.

@nl

P1476

Somatic BRCA1 mutations in cli ...... dullary histological features.

@en

P2093

Bernhard Pestalozzi

http://www.w3.org/2001/XMLSchema#string

Bettina Sobottka

http://www.w3.org/2001/XMLSchema#string

Daniel Fink

http://www.w3.org/2001/XMLSchema#string

Holger Moch

http://www.w3.org/2001/XMLSchema#string

Konstantin Dedes

http://www.w3.org/2001/XMLSchema#string

Markus Rechsteiner

http://www.w3.org/2001/XMLSchema#string

Peter Wild

http://www.w3.org/2001/XMLSchema#string

P2860

Atypical medullary carcinoma of the breast has similar prognostic factors and survival to typical medullary breast carcinoma: 3,976 cases from the National Cancer Data Base.

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification

Functional assays for classification of BRCA2 variants of uncertain significance.

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.

Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.

P2888

s00432-018-2609-5

P304

865-874

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00432-018-2609-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

144

http://www.w3.org/2001/XMLSchema#string

P50

Zsuzsanna Varga

P577

2018-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29453630

http://www.w3.org/2001/XMLSchema#string

P932

5916977

http://www.w3.org/2001/XMLSchema#string